Intra-Cellular Therapies (ITCI) IV into FDA decision on Caplyta
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Up)Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) 30-day option implied volatility is at 70; compared to its 52-week range of 53 to 111 into FDA decision on Caplyta.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- Colgate-Palmolive (CL) April weekly option implied volatility into quarter results
- Skechers USA (SKX) August 55 puts active
Create E-mail Alert Related Categories
OptionsRelated Entities
The Children's Investment Fund (TCI), Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
